Pharmacokinetics of FK 506: preclinical and clinical studies.

PubWeight™: 2.48‹?› | Rank: Top 2%

🔗 View Article (PMC 2903896)

Published in Transplant Proc on February 01, 1990

Authors

R Venkataramanan1, A Jain, E Cadoff, V Warty, K Iwasaki, K Nagase, A Krajack, O Imventarza, S Todo, J J Fung

Author Affiliations

1: School of Pharmacy, University of Pittsburgh, PA 15261.

Articles citing this

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69

Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41

Pharmacokinetics of FK 506 in transplant patients. Transplant Proc (1991) 1.30

Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis (2008) 1.27

Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23

FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc (1991) 1.01

The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. Transplantation (1992) 0.98

Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol (2001) 0.95

Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93

FK 506 and autoimmune disease: perspective and prospects. Autoimmunity (1992) 0.85

Distribution of FK 506 in plasma lipoproteins in transplant patients. Transplant Proc (1991) 0.85

Esophageal complications in orthotopic liver transplant patients. Transplantation (1991) 0.84

Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. J Clin Invest (1996) 0.83

Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc (1991) 0.83

Recent advances in hepatic transplantation at the University of Pittsburgh. Clin Transpl (1993) 0.83

Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. Transplant Proc (1991) 0.80

Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. Transplant Proc (1991) 0.79

Automatic identification and normalization of dosage forms in drug monographs. BMC Med Inform Decis Mak (2012) 0.78

Acute overdoses of tacrolimus (FK 506). Dig Dis Sci (1999) 0.78

Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol (2016) 0.77

Different influences on tacrolimus pharmacokinetics by coadministrations of zhi ke and zhi shi in rats. Evid Based Complement Alternat Med (2011) 0.77

In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol (1991) 0.75

Effect of renal ischemia on plasma levels of FK 506 in rats. Transplant Proc (1992) 0.75

The Diabetic Dog as a Translational Model for Human Islet Transplantation
. Yale J Biol Med (2017) 0.75

Articles cited by this

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45

Kidney transplantation under FK 506. JAMA (1990) 7.45

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol (2001) 4.81

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Sequence of 3,687 nucleotides from the 3' end of Sendai virus genome RNA and the predicted amino acid sequences of viral NP, P and C proteins. Nucleic Acids Res (1983) 3.62

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

N-linked oligosaccharides are not involved in the function of a cell-cell binding glycoprotein E-cadherin. Cell Struct Funct (1986) 2.90

Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75

The relationship of physical fitness to lipid and lipoprotein(a) levels in adolescents with IDDM. Diabetes Care (1993) 2.70

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Res (1986) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Translation of the genetic message. VII. Role of initiation factors in formation of the chain initiation complex with Escherichia coli ribosomes. Arch Biochem Biophys (1968) 2.46

Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40

Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

Three-step method for ultrasound-guided central vein catheterization. Br J Anaesth (2012) 2.35

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31